Prognosis Research: A Strategic Initiative in Translational Pathways (PROGRESS)

临床调查的一种基本形式包括在一个时间点描述患有疾病或疾病的人的特征，并对他们进行跟踪，以了解他们在另一个时间点是否以及为什么会进展。这样的预后研究对于理解如何翻译？改善健康的新方法，从最初的发现到评价阶段，并酌情进入临床实践。预后研究应补充和增加MRC战略目标的价值，涉及：遗传学，生物标志物，福祉，健康记录和基于人口的数据的利用以及转化研究。但是，在不同疾病领域进行的大量系统综述表明，预后研究的前景与其实现能力之间存在差距。作为对此的回应，我们在BMJ/PloSMed上发表了一系列即将发表的6篇文章，其中列出了预后研究的框架并提出了建议。目的：PROGRESS伙伴关系的目的是在不同疾病领域批判性地发展和系统地应用概念、方法和建议（来自最初的PROGRESS文章系列和其他地方），以增强预后研究的转化影响。我们将通过在转译预后研究方面建立一个新的国际联盟来实现这一目标。该伙伴关系的研究人员（来自6篇文章系列的作者）目前领导了6600万美元的预后研究经费。在MRC的支持下，跨疾病领域和方法学学科将建立国际伙伴关系。合作伙伴关系工作流合作伙伴关系将提供三个相互关联的、里程碑驱动的工作流：1 .使能活动，通过有针对性的研讨会，我们寻求(a)推进分层医学的方法开发，寻求针对那些将受益最大的患者的治疗；(b)提高科学论文中预后研究报告的开放性（透明度）；(c)确定跨临床队列进行更好研究的机会；(d)传播伙伴关系的研究成果（知识转移）。我们将开展新的研究，重点关注预后研究在我们整个伙伴关系翻译中重要的例子。我们将回顾已发表的文献（知识综合），并在我们自己的临床队列中进行新的分析。其中包括为5万多名患有不同疾病的患者提供新的机会：冠状动脉疾病；癌症，外伤和分娩时的急性大出血以及肌肉骨骼疾病。我们将开发一系列的教学课程、更高的学位和奖学金机会，培养未来国内和国际预后研究的领导者。

Strategic importance A basic form of clinical enquiry involves characterising people with disease or illness at one time point and following them up to see whether and why they have progressed at another time point. Such prognosis research is important in understanding how to ?translate? new approaches to improving health from initial discovery, through phases of evaluation and, where appropriate, into clinical practice. Prognosis research should complement and add value to MRC strategic aims, relating to: genetics, biomarkers, wellbeing, exploitation of health records and population based data and translational research. But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations. Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research. Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines. Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.